PlainPill

GLP-1 Agonists

The short answer. There isn't much data on GLP-1 Agonists yet — 11 mentions, 8 with a clear outcome — so treat these numbers as anecdotal. It is most often used for weight loss: 100% of 6 reports say that improved. It is well studied — 102 meta-analyses on PubMed.

What users report
63%helped8 reports · few reports
5 helped3 mixed0 didn't help

From 11 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
102
meta-analyses
20
RCTs
1,267
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What GLP-1 Agonists does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 102 meta-analyses on PubMed ↗ · 20 randomized trials ↗

J Diabetes Complications · 2024 · Meta-analysis / systematic review
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials

Conclusion: The use of GLP1-RAs demonstrates efficacy in reducing BMI, triglycerides, waist circumference and total testosterone. There was no significant difference in total cholesterol and HOMA-IR levels. These results signify its viability as a favourable treatment option for managing PCOS symptoms in women living with obesity.

PubMed 39178623 ↗
Nutrients · 2025 · Meta-analysis / systematic review
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review

Conclusion: Thirty-eight studies were included in this systematic review. GLP-1 analogues have demonstrated a notable impact on the composition, richness, and diversity of gut microbiota. We can conclude, following the obtained research results of our study, that liraglutide promotes the growth of beneficial genera relevant for beneficial metabolic functions. Exenatide and exendin-4 administration showed various effects on the microbiome composition in animal and human studies. In animal models, it increased genera associated with improved metabolism; however, in human models, genera linked to better meta

PubMed 40284168 ↗
Eat Weight Disord · 2025 · Meta-analysis / systematic review
The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis

Conclusion: This review underscores the potential role of GLP-1 agonists in BED management. However, given the limited data, especially concerning EDs other than BED and the long-term effects of these medications, further comprehensive clinical trials are recommended to evaluate the impact of various GLP-1 agonists on different EDs across diverse demographic groups.

PubMed 39891848 ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

US government research funding (NIH)

NIH has funded 2 research projects with GLP-1 Agonists in the title, $2,702,157 in total (2021–2026). NIH RePORTER ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

gastroparesis ×1ileus ×1intestinal obstruction ×1gallbladder injury ×1vomiting ×1acid reflux ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

Other options for weight loss

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate